FI930774A7 - Endoteliinin sufonamidiantagonistit - Google Patents

Endoteliinin sufonamidiantagonistit Download PDF

Info

Publication number
FI930774A7
FI930774A7 FI930774A FI930774A FI930774A7 FI 930774 A7 FI930774 A7 FI 930774A7 FI 930774 A FI930774 A FI 930774A FI 930774 A FI930774 A FI 930774A FI 930774 A7 FI930774 A7 FI 930774A7
Authority
FI
Finland
Prior art keywords
endothelin
sulfonamide
antagonists
sulfonamide antagonists
endothelin sulfonamide
Prior art date
Application number
FI930774A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI930774A0 (fi
FI930774L (fi
Inventor
Philip D Stein
John T Hunt
Natesan Murugesan
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of FI930774A0 publication Critical patent/FI930774A0/fi
Publication of FI930774L publication Critical patent/FI930774L/fi
Publication of FI930774A7 publication Critical patent/FI930774A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Glass Compositions (AREA)
FI930774A 1992-02-24 1993-02-22 Endoteliinin sufonamidiantagonistit FI930774A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84049692A 1992-02-24 1992-02-24

Publications (3)

Publication Number Publication Date
FI930774A0 FI930774A0 (fi) 1993-02-22
FI930774L FI930774L (fi) 1993-08-25
FI930774A7 true FI930774A7 (fi) 1993-08-25

Family

ID=25282528

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930774A FI930774A7 (fi) 1992-02-24 1993-02-22 Endoteliinin sufonamidiantagonistit

Country Status (26)

Country Link
EP (1) EP0558258B1 (enExample)
JP (1) JP3273818B2 (enExample)
KR (1) KR100257134B1 (enExample)
CN (1) CN1044235C (enExample)
AT (1) ATE152713T1 (enExample)
AU (1) AU651922B2 (enExample)
CA (1) CA2089184A1 (enExample)
CY (1) CY2045B1 (enExample)
DE (1) DE69310414T2 (enExample)
DK (1) DK0558258T3 (enExample)
EG (1) EG20143A (enExample)
ES (1) ES2103061T3 (enExample)
FI (1) FI930774A7 (enExample)
GR (1) GR3024203T3 (enExample)
HK (1) HK121597A (enExample)
HU (1) HU219455B (enExample)
IL (1) IL104748A (enExample)
MX (1) MX9300842A (enExample)
MY (1) MY109004A (enExample)
NO (1) NO303012B1 (enExample)
NZ (1) NZ245905A (enExample)
PH (1) PH30795A (enExample)
PL (1) PL172035B1 (enExample)
RU (1) RU2116301C1 (enExample)
TW (1) TW224462B (enExample)
ZA (1) ZA93780B (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
FI941826L (fi) 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US5391566A (en) * 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
ES2081251B1 (es) * 1993-08-04 1996-10-16 Squibb & Sons Inc Antagonistas de endotelina, a base de sulfonamida.
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
BR9407933A (pt) * 1993-11-01 1996-11-26 Japat Ltd Antagonistas de receptores de endotelina
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
EP0819125B1 (en) * 1995-04-04 2003-06-18 Texas Biotechnology Corporation Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
AU717230B2 (en) 1996-02-20 2000-03-23 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
TW402597B (en) * 1996-02-20 2000-08-21 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides
US5958905A (en) 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TR200202738T2 (tr) 1997-04-28 2003-03-21 Texas Biotechnology Corporation Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
JP3783411B2 (ja) 1997-08-15 2006-06-07 富士ゼロックス株式会社 表面発光型半導体レーザ
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CA2367916A1 (en) 1999-03-19 2000-09-28 Ambarish Singh Methods for the preparation of biphenyl isoxazole sulfonamides
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
SK9532002A3 (en) 1999-12-31 2003-06-03 Texas Biotechnology Corp Sulfonamides and derivatives thereof that modulate the activity of endothelin
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
JP4293734B2 (ja) * 2001-01-17 2009-07-08 三菱電機株式会社 電動式パワーステアリング制御装置
EP1402890B1 (en) * 2001-06-08 2008-01-09 Institute of Medicinal Molecular Design, Inc. Sulfonamide derivatives
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
DE10256186A1 (de) * 2002-12-02 2004-06-09 Bayer Ag Cyclopenta(c)isoxazol-3-amine als Materialschutzmittel
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2006046916A1 (en) * 2004-10-29 2006-05-04 Astrazeneca Ab Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
US8541592B2 (en) 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
EP2051977A2 (en) 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
JP4518065B2 (ja) * 2006-10-25 2010-08-04 宇部興産株式会社 新規ジアルコキシアミドオキシム誘導体及びその製法
JP4518066B2 (ja) * 2006-10-25 2010-08-04 宇部興産株式会社 ジアルコキシニトリル誘導体及びその製法
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
UY31832A (es) 2008-05-20 2010-01-05 Astrazeneca Ab Derivados de indazol sustituidos con fenilo y benzodioxinilo
CN101818056B (zh) * 2010-05-27 2013-07-31 中南大学 一类丹磺酰类分子探针及其合成方法和应用
TW201336496A (zh) * 2012-01-31 2013-09-16 Eisai R&D Man Co Ltd 西他生坦（Ｓｉｔａｘｅｎｔａｎ）衍生物
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
SI4299135T1 (sl) 2019-06-18 2025-12-31 Pfizer Inc. Benzizoksazolni sulfonamidni derivati

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2888455A (en) * 1956-09-04 1959-05-26 Shionogi & Co New sulfonamide and process for producing the same
US3300488A (en) * 1963-12-23 1967-01-24 Shionogi & Co Nu, nu'-bis [4-halogenated-5-alkyl-3-isoxazolylsulfamoyl)-phenyl]-ureas
US3422095A (en) * 1966-11-04 1969-01-14 Hoffmann La Roche N**1-and/or n**4-(lower alkoxyacetyl) sulfanilamides
GB1473433A (enExample) * 1975-10-09 1977-05-11 Banyu Pharmaceutical Co Ltd Hi
FI97540C (fi) * 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
TW270116B (enExample) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина

Also Published As

Publication number Publication date
DK0558258T3 (da) 1997-05-26
RU2116301C1 (ru) 1998-07-27
EP0558258B1 (en) 1997-05-07
AU651922B2 (en) 1994-08-04
IL104748A0 (en) 1993-06-10
JPH069585A (ja) 1994-01-18
HK121597A (en) 1997-09-12
CN1079468A (zh) 1993-12-15
CY2045B1 (en) 1998-04-30
HU219455B (hu) 2001-04-28
KR100257134B1 (ko) 2000-05-15
MY109004A (en) 1996-11-30
ZA93780B (en) 1993-09-08
NO303012B1 (no) 1998-05-18
TW224462B (enExample) 1994-06-01
AU3319293A (en) 1993-08-26
NO930633L (no) 1993-08-25
FI930774A0 (fi) 1993-02-22
MX9300842A (es) 1993-08-01
HU9300491D0 (en) 1993-05-28
CA2089184A1 (en) 1993-08-25
FI930774L (fi) 1993-08-25
PL172035B1 (pl) 1997-07-31
JP3273818B2 (ja) 2002-04-15
PL297820A1 (en) 1993-09-06
HUT65762A (en) 1994-07-28
ES2103061T3 (es) 1997-08-16
GR3024203T3 (en) 1997-10-31
DE69310414T2 (de) 1997-12-11
KR930017881A (ko) 1993-09-20
NO930633D0 (no) 1993-02-23
DE69310414D1 (de) 1997-06-12
IL104748A (en) 1996-10-16
CN1044235C (zh) 1999-07-21
EG20143A (en) 1997-07-31
PH30795A (en) 1997-10-17
NZ245905A (en) 1995-07-26
EP0558258A1 (en) 1993-09-01
ATE152713T1 (de) 1997-05-15

Similar Documents

Publication Publication Date Title
NO943190L (no) Sulfonamid-endothelin-antagonister
FI961804A0 (fi) Endoteliinireseptoriantagonistit
DE69327720D1 (de) Endothelin rezeptor antagonisten
FI942090A0 (fi) Sulfonamidiherbisidit
FI935555L (fi) Uusia sulfonamideja
FI932518A7 (fi) Angiotensiinin II antagonistit
DK0612244T3 (da) Endothelinreceptorantagonister
NO932005D0 (no) Angiotensin-ii-antagonister
FI960516A0 (fi) Substituoituja bifenyylisulfonamidiendoteliiniantagonisteja
FI934300A7 (fi) Bradykiniiniantagonisteja
ATE213156T1 (de) Endothelin-rezeptor-antagonisten
MX9100717A (es) Antagonistas de la bradiquinina
KR950703530A (ko) 5-HT4 길항제(5-HT4 Antagonists)
NO20000542L (no) Endothelin-antagonister
FI944905A7 (fi) Endoteliiniantagonistit II
DE69316307D1 (de) Vibrator
FI930108A0 (fi) Imidazopyridin-paf-antagonister
FI98103B (fi) Stallarakenne
ES1020236Y (es) Envase-dosificador
FI925274A0 (fi) Vibrator
SE9202711D0 (sv) Massageapparat
BR1100494A (pt) Antagonistas de ige
SE9200886D0 (sv) Containerkonstruktion